Clinical Trial Update: Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the effectiveness of combining DKN-01 (a DKK1 inhibitor) with pembrolizumab in advanced or recurrent endometrial cancer. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• DKN-01 (dkn-01)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Endometrial Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING